Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. These regulatory documents offer detailed information on the company’s financial condition, clinical development activities, risk factors and corporate governance.
Through periodic reports such as Forms 10-Q and 10-K, Pliant describes research and development spending, progress in programs like bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis, PLN-101095 for solid tumors and PLN-101325 for muscular dystrophies, as well as broader platform efforts in integrin-based drug discovery. Current reports on Form 8-K, including those referenced in the provided data, disclose specific material events such as financial results for a quarter, voluntary prepayment and termination of a loan agreement, changes in executive leadership roles and other significant corporate actions.
Investors can also review filings that discuss strategic realignments of workforce and operations, cash runway considerations and references to risk factors and management’s discussion and analysis sections, which Pliant points to in its press releases. For those tracking equity and governance details, the company’s registration of common stock and related rights on The Nasdaq Stock Market LLC is reflected in its SEC submissions.
On Stock Titan, these filings are available alongside AI-powered summaries that highlight key points, helping readers interpret lengthy documents such as annual and quarterly reports or event-driven 8-Ks. Real-time updates from the SEC’s EDGAR system, combined with structured access to filings related to financial results, material agreements and leadership changes, allow users to follow how Pliant’s disclosures develop over time.
Kenneth Griffin and affiliated Citadel entities report a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. common stock. The group may be deemed to beneficially own 3,042,133 Shares, based on 61,449,385 Shares outstanding as of November 1, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 2,099,798 Shares, while Citadel Securities LLC may be deemed to own 913,609 Shares. All reporting persons have shared, but not sole, voting and dispositive power over their respective positions and certify the holdings are not for the purpose of changing or influencing control of Pliant.
Citadel-affiliated entities and Kenneth Griffin report a significant but sub-5% passive stake in Pliant Therapeutics, Inc. They collectively may be deemed to beneficially own 3,037,695 common shares, equal to 4.9% of the company’s stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and related vehicles. All voting and dispositive powers are shared, and the reporting persons certify the holdings were not acquired to change or influence control of Pliant.
Pliant Therapeutics reported that its Chief Financial Officer, Keith Lamont Cummings, received a new stock option grant. The option allows him to buy 400,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036. According to the vesting terms, 1/48th of the shares vest and become exercisable on each monthly anniversary of January 1, 2026, as long as he continues to serve the company. After this award, he holds 400,000 stock options directly.
Pliant Therapeutics, Inc. reported that its Chief Operating Officer, Minnie Kuo, received a stock option grant for 300,000 shares of common stock. The option has an exercise price of $1.30 per share and was granted on January 22, 2026, with an expiration date of January 22, 2036. No purchase price was paid for the grant itself.
According to the vesting terms, 1/48th of the option vests and becomes exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as Kuo continues to provide service to the company on each vesting date. After vesting, the option allows her to buy Pliant common shares at the fixed exercise price within the option term.
Pliant Therapeutics granted its Chief Human Resource Officer, Lily Cheung, a stock option on January 22, 2026. The option gives her the right to buy 300,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as she continues serving the company. After this grant, she directly holds 300,000 stock options.
Pliant Therapeutics President and CEO Bernard Coulie received a grant of stock options covering 1,230,000 shares of common stock on January 22, 2026. The options have an exercise price of $1.30 per share and are held directly. According to the vesting terms, 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, contingent on his continued service with the company.
Pliant Therapeutics’ Chief Financial Officer Keith Lamont Cummings reported an automatic sale of company stock. On January 20, 2026, a plan sold 24,002 shares of Common Stock on his behalf at a weighted average price of
The shares were sold by a broker over a price range of
Pliant Therapeutics Chief Human Resource Officer Lily Cheung reported a sale of company stock under a tax-withholding plan. On January 20, 2026, a company plan sold 7,534 shares of Common Stock on her behalf at a weighted-average price of $1.28 per share, in transactions intended to comply with Rule 10b5-1. The sales were executed between $1.245 and $1.33 over several days to cover withholding taxes tied to the vesting of previously granted restricted stock units.
After these transactions, Cheung beneficially owned 44,847 shares of Pliant Therapeutics Common Stock. This total includes 1,956 shares acquired through an Employee Stock Purchase Plan program, showing she continues to hold a meaningful equity position in the company.
Pliant Therapeutics President and CEO Bernard Coulie reported a sale of 89,375 shares of common stock on January 20, 2026 at a weighted average price of
After this transaction, Coulie directly beneficially owns 505,601 shares of common stock, which include 1,959 shares acquired through an employee stock purchase program. He is also reported as indirectly owning 409,317 shares held by The Coulie/Leyman Family Trust, where he and his spouse serve as trustees; he disclaims beneficial ownership of those shares beyond his pecuniary interest.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share. This was a nondiscretionary sale by a plan under Rule 10b5-1, carried out by a broker as part of transactions at prices ranging from $1.245 to $1.33 between January 20 and January 22, 2026. The sales were made on behalf of a group of employees, including Kuo, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock directly.
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
